Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenosine deaminase domain-containing protein 2 (ADAD2) is a testis-specific RNA-binding protein characterized by a catalytically inactive adenosine deaminase domain and implicated as a key regulator of male germ cell differentiation. Unlike classical adenosine deaminases, ADAD2 does not exhibit enzymatic activity but is essential for the progression of meiotic spermatocytes to spermatids, with loss-of-function mutations causing maturation arrest and complete male infertility in animal models. ADAD2 is expressed almost exclusively in pachytene spermatocytes within the testis, and its deficiency is associated with sperm development disorders. There are no known therapeutic interventions directed at ADAD2, nor is it implicated in signaling pathways typical of pharmacologic targets[1][3][5].
Not applicable; ADAD2 is not targeted by therapeutic drugs
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenosine deaminase domain-containing protein 2 (ADAD2).